KalshiFinancials

FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)

FDA decision on Bepirovirsen in 2026

Ends Jan 1, 2027

Disclosure

18+ only. Event contracts carry significant risk and are not suitable for everyone, you can lose the entire amount you commit. Not available in all jurisdictions; restrictions and eligibility requirements apply.

Probability

a full approval or an accelerated approval2.6K VOL.
Yes 98%No 2%
98¢

Rules Summary

If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Timeline and Payout

Opened: Jun 17, 2026, 9:00 PM
Closes: Jan 1, 2027, 4:59 AM
Pays out: 0.5 hours after close

Series KXBEPIROVIRSEN · Event KXBEPIROVIRSEN-27 · Market KXBEPIROVIRSEN-27-Y